AstraZeneca has agreed to lower costs of some medicines in exchange for a three-year reprieve from US President Donald Trump’s tariffs.
As part of the deal the pharmaceutical company will cut drug costs for Americans on Medicaid, the government-backed insurance programme for low-income people, and reduce the prices of some recently launched drugs.
It will also sell more of its medicines directly to patients on its own site and the recently launched TrumpRx. The agreement requires AstraZeneca to repatriate to the US some profits it earns abroad if foreign drug prices increase as a result of the deal.
您已阅读30%（604字），剩余70%（1417字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。